Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts
Portfolio Pulse from Benzinga Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 5 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $26.0, with a high of $31.00 and a low of $20.00. Recent analyst actions include rating adjustments and price target changes, reflecting evolving market dynamics and company performance. Financially, ACADIA has shown a 73.75% revenue growth rate, a net margin of 8.04%, and a debt-to-equity ratio of 0.13.
August 07, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ACADIA Pharmaceuticals has received mixed analyst ratings with an average 12-month price target of $26.0. Recent financials show strong revenue growth and profitability, but analysts have adjusted their ratings and price targets in response to market dynamics.
The mixed analyst ratings and adjustments in price targets indicate uncertainty in the short-term outlook for ACADIA Pharmaceuticals. While the company shows strong financial metrics, the diverse range of analyst opinions suggests a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100